ALTASCIENCES CLINICAL KANSAS INC

Altasciences Clinical Kansas Inc. specializes in early-phase clinical research and development for novel therapeutic agents, with deep expertise in pharmacokinetic and pharmacodynamic studies, single ascending dose trials, and drug interaction analyses. The company delivers rigorous Phase I clinical research services focused on substance use disorders and investigational compounds, including opioid alternatives and alkaloid-based therapeutics. Their technical capabilities encompass human pharmacology, bioanalytical assay design, data acquisition in controlled clinical settings, and regulatory-compliant study execution under IND protocols. A key differentiator is their focus on complex, high-risk compounds such as kratom alkaloids and cocaine analogs, requiring specialized metabolic and safety profiling expertise not commonly found in general CROs. The contractor maintains a sustained and trusted relationship with the Department of Health and Human Services, consistently supporting research initiatives under the National Institute on Drug Abuse and other HHS components. Their work centers on advancing medication development for addiction treatment through tightly controlled human studies, demonstrating a proven ability to navigate complex regulatory pathways and execute sensitive, federally funded clinical research. Their primary NAICS classification—541715—reflects a focused niche in non-biotech, non-nanotech life sciences R&D, specifically in clinical pharmacology and early-stage drug evaluation. This positions them as a specialized provider for federal agencies seeking high-quality, human-subject pharmacology data to support FDA submission packages and therapeutic innovation in addiction medicine. Altasciences Clinical Kansas Inc. operates as a small, privately held entity (2L structure) based in Overland Park, Kansas. While it holds no formal government certifications, its consistent performance on high-stakes HHS contracts demonstrates reliability and regulatory competence. The firm’s geographic presence in the Midwest supports national clinical trial networks while maintaining operational agility for time-sensitive, federally sponsored studies.